LONDON/ZURICH (Reuters) – Roche Holding AG (ROG.VX) has agreed to buy U.S. The Swiss drugmaker said on Sunday it would pay $74.00 a share through a tender offer for InterMune, representing a premium of 38 percent to the closing price on Aug. 22. The sale of InterMune will not come as a huge surprise to investors as people familiar with the matter said on Aug. 13 that InterMune was working with financial advisers to evaluate strategic options, due to takeover interest from big drugmakers.